Morgan Stanley raised the firm’s price target on GSK to 1,585 GBp from 1,440 GBp and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- Scynexis recalling Brexafemme from market, placing temporary hold on studies
- Japan’s MHLW approves GSK’s Arexvy for adults 60 years and older
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Procter & Gamble Stock (NYSE:PG): Quality Comes at a Hefty Price
- Citi sees Incyte’s Jakafi remaining dominant after GSK approval